Genprex Reveals Positive Preclinical Data Showing Synergies to Fight Lung Cancers

Genprex’s CEO discusses data presented by its collaborators at The University of Texas MD Anderson Cancer Center at the recent AACR Tumor Immunology and Immunotherapy Meeting, highlighting how the positive preclinical data shows that Genprex’s TUSC2 gene could help fight some of the most resistant metastatic lung cancers.